Sex Steroids and Skeletal Health in Men

Osteoporosis and the Osteoporosis of Rheumatic Diseases

Volumn , Issue , 2006, Pages 145-156

  Meier, Christian ^a   Liu, Peter Y ^b   Seibel, Markus J ^b   Handelsman, David J ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751220905     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03437-1.50022-1     Document Type: Chapter

References (116)

1. Cooper C, Campion G, Melton LJ Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992, 2:285-289.
2. Gullberg B, Johnell O, Kanis JA World-wide projections for hip fracture. Osteoporos Int 1997, 7:407-413.
3. Jones G, Nguyen T, Sambrook PN, et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994, 4:277-282.
4. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
5. Bilezikian JP Osteoporosis in men. J Clin Endocrinol Metab 1999, 84:3431-3434.
6. Handelsman DJ Androgen action and pharmacologic uses. Endocrinology 2001, 2232-2242. W.B. Saunders, Philadelphia. L. DeGroot (Ed.).
7. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004, 25:389-425.
8. de Ronde W, Pols HA, van Leeuwen JP, et al. The importance of oestrogens in males. Clin Endocrinol (Oxf) 2003, 58:529-542.
9. Purohit A, Flanagan AM, Reed MJ Estrogen synthesis by osteoblast cell lines. Endocrinology 1992, 131:2027-2029.
10. Saito H, Yanaihara T Steroid formation in osteoblast-like cells. J Int Med Res 1998, 26:1-12.
11. Janssen JM, Bland R, Hewison M, et al. Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biochem 1999, 75:528-537.
12. Sasano H, Uzuki M, Sawai T, et al. Aromatase in human bone tissue. J Bone Miner Res 1997, 12:1416-1423.
13. Shozu M, Simpson ER Aromatase expression of human osteoblast-like cells. Mol Cell Endocrinol 1998, 139:117-129.
14. Oz OK, Millsaps R, Welch R, et al. Expression of aromatase in the human growth plate. J Mol Endocrinol 2001, 27:249-253.
15. Gennari L, Nuti R, Bilezikian JP Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004, 89:5898-5907.
16. Van Der Eerden BC, Van De Ven J, Lowik CW, et al. Sex steroid metabolism in the tibial growth plate of the rat. Endocrinology 2002, 143:4048-4055.
17. Shimodaira K, Fujikawa H, Okura F, et al. Osteoblast cells (MG-63 and HOS) have aromatase and 5 alpha-reductase activities. Biochem Mol Biol Int 1996, 39:109-116.
18. Schweikert HU, Rulf W, Niederle N, et al. Testosterone metabolism in human bone. Acta Endocrinol (Copenh) 1980, 95:258-264.
19. Issa S, Schnabel D, Feix M, et al. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab 2002, 87:5401-5407.
20. Feix M, Wolf L, Schweikert HU Distribution of 17beta-hydroxy-steroid dehydrogenases in human osteoblast-like cells. Mol Cell Endocrinol 2001, 171:163-164.
21. Kuwano Y, Fujikawa H, Watanabe A, et al. 3Beta-hydroxysteroid dehydrogenase activity in human osteoblast-like cells. Endocr J 1997, 44:847-853.
22. Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A 1989, 86:854-857.
23. Abu EO, Horner A, Kusec V, et al. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997, 82:3493-3497.
24. Mizuno Y, Hosoi T, Inoue S, et al. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif Tissue Int 1994, 54:325-326.
25. Pederson L, Kremer M, Judd J, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A 1999, 96:505-510.
26. Hofbauer LC, Khosla S Androgen effects on bone metabolism: recent progress and controversies. Eur J Endocrinol 1999, 140:271-286.
27. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988, 241:84-86.
28. Bord S, Horner A, Beavan S, et al. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab 2001, 86:2309-2314.
29. Green S, Walter P, Greene G, et al. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 1986, 24:77-83.
30. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925-5930.
31. Gray A, Berlin JA, McKinlay JB, et al. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991, 44:671-684.
32. Liu PY, Swerdloff RS, Veldhuis J The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab 2004, 89:4789-4796.
33. Ly LP, Handelsman DJ Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005, 152:471-478.
34. Kaufman JM, Vermeulen A Declining gonadal function in elderly men. Baillieres Clin Endocrinol Metab 1997, 11:289-309.
35. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86:724-731.
36. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87:589-598.
37. Liu PY, Death AK, Handelsman DJ Androgens and cardiovascular disease. Endocr Rev 2003, 24:313-340.
38. Testosterone and Aging: Clinical Research Directions 2003, National Academic Press, Washington, D.C. C.T. Liverman, D.G. Blazer (Eds.).
39. Vermeulen A, Kaufman JM, Goemaere S, et al. Estradiol in elderly men. Aging Male 2002, 5:98-102.
40. Khosla S, Melton LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274.
41. Seibel MJ, Eastell R, Grundberg CM, et al. Biochemical markers of bone metabolism. Principles of Bone Biology 2002, 1543-1571. Academic Press, San Diego. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
42. Leder BZ, Finkelstein JS Gonadal steroids and the skeleton in men. Contemporary Endocrinology. Osteoporosis: Pathophysiology and Clinical Management 2003, 393-411. Humana Press, Totowa, NJ. E.S. Orwoll, M. Bliziotes (Eds.).
43. Stepan JJ, Lachman M, Zverina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989, 69:523-527.
44. Goldray D, Weisman Y, Jaccard N, et al. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993, 76:288-290.
45. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948-955.
46. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001, 86:2787-2791.
47. Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998, 83:1561-1566.
48. Basaria S, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56:779-786.
49. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656-3661.
50. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999, 54:607-611.
51. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999, 45:1240-1247.
52. Daniell HW Osteoporosis after orchiectomy for prostate cancer. J Urol 1997, 157:439-444.
53. Kiratli BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001, 57:127-132.
54. Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997, 79:545-550.
55. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000, 86:449-452.
56. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001, 166:1724-1728.
57. Melton LJ, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003, 169:1747-1750.
58. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841-3846.
59. Lopez AM, Pena MA, Hernandez R, et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005, 16:707-711.
60. Francis RM The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf) 1999, 50:411-414.
61. Smith DA, Walker MS Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif Tissue Res 1977, 22(Suppl):225-228.
62. Foresta C, Ruzza G, Mioni R, et al. Testosterone and bone loss in Klinefelter syndrome. Horm Metab Res 1983, 15:56-57.
63. Horowitz M, Wishart JM, O'Loughlin PD, et al. Osteoporosis and Klinefelter's syndrome. Clin Endocrinol (Oxf) 1992, 36:113-118.
64. Greenspan SL, Neer RM, Ridgway EC, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986, 104:777-782.
65. Luisetto G, Mastrogiacomo I, Bonanni G, et al. Bone mass and mineral metabolism in Klinefelter's syndrome. Osteoporos Int 1995, 5:455-461.
66. Bojesen A, Juul S, Gravholt CH Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2003, 88:622-626.
67. Jackson JA, Kleerekoper M, Parfitt AM, et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987, 65:53-58.
68. Guo CY, Jones TH, Eastell R Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 1997, 82:658-665.
69. Baran DT, Bergfeld MA, Teitelbaum SL, et al. Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif Tissue Res 1978, 26:103-106.
70. Francis RM, Peacock M, Aaron JE, et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 1986, 7:261-268.
71. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996, 81:3654-3662.
72. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001, 54:739-750.
73. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85:2670-2677.
74. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996, 81:4358-4365.
75. Morley JE, Perry HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993, 41:149-152.
76. Aminorroaya A, Kelleher S, Conway AJ, et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005, 152:881-886.
77. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994, 331:1056-1061.
78. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995, 80:3689-3698.
79. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997, 337:91-95.
80. Maffei L, Murata Y, Rochira V, et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004, 89:61-70.
81. Greenspan SL, Oppenheim DS, Klibanski A Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989, 110:526-531.
82. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82:2386-2390.
83. Leifke E, Korner HC, Link TM, et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998, 138:51-58.
84. Devogelaer JP, De Cooman S, Nagant de Deuxchaisnes C Low bone mass in hypogonadal males: effect of testosterone substitution therapy, a densitometric study. Maturitas 1992, 15:17-23.
85. Isaia G, Mussetta M, Pecchio F, et al. Effect of testosterone on bone in hypogonadal males. Maturitas 1992, 15:47-51.
86. Zitzmann M, Depenbusch M, Gromoll J, et al. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 2004, 89:6208-6217.
87. Seeman E The growth and age-related origins of bone fragility in men. Calcif Tissue Int 2004, 75:100-109.
88. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000, 85:2839-2853.
89. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89:2085-2098.
90. Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004, 89:3821-3829.
91. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997, 82:407-413.
92. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82:1661-1667.
93. Bhasin S, Singh AB, Mac RP, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299-311.
94. Handelsman DJ Trends and regional differences in testosterone prescribing in Australia, 1991-2001. Med J Aust 2004, 181:419-422.
95. Handelsman DJ, Liu PY Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab 2005, 16:39-45.
96. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001, 86:192-199.
97. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997, 100:1755-1759.
98. Khosla S, Melton LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001, 86:3555-3561.
99. Gennari L, Merlotti D, Martini G, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003, 88:5327-5333.
100. Riggs BL, Khosla S, Melton LJ Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279-302.
101. Khosla S, Melton LJ, Riggs BL Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 2002, 87:1443-1450.
102. Greendale GA, Edelstein S, Barrett-Connor E Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997, 12:1833-1843.
103. Kenny AM, Prestwood KM, Marcello KM, et al. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 2000, 55:M492-M497.
104. Goderie-Plomp HW, van der Klift M, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 2004, 89:3261-3269.
105. Tenover JS Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992, 75:1092-1098.
106. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:1966-1972.
107. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004, 89:503-510.
108. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001, 56:M266-M272.
109. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106:1553-1560.
110. Doran PM, Riggs BL, Atkinson EJ, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001, 16:2118-2125.
111. Meier C, Liu PY, Ly LP, et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004, 89:3033-3041.
112. Leder BZ, LeBlanc KM, Schoenfeld DA, et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003, 88:204-210.
113. Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003, 88:3167-3176.
114. Anderson RA, Wallace AM, Sattar N, et al. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 2003, 88:2784-2793.
115. Seibel MJ Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003, 32:83-113. vi-vii.
116. Meier C, Liu PY, Handelsman DJ, et al. Endocrine regulation of bone turnover in men. Clin Endocrinol (Oxf) 2005, 63:603-616.